US 6037153A
· Izumori et al.
· 2000
[cited by applicant]
US 6077832A
· Chamberlain et al.
· 2000
[cited by applicant]
US 6469160B1
· Glover et al.
· 2002
[cited by applicant]
US 6482939B1
· Hodgson et al.
· 2002
[cited by applicant]
US 8541391B2
· Amparo et al.
· 2013
[cited by applicant]
US 8546344B2
· Coquerel et al.
· 2013
[cited by applicant]
US 8940707B2
· Peabody
· 2015
[cited by applicant]
US 20150126470A1
· Peabody, III
· 2015
[cited by applicant]
US 20160175338A1
· Peabody, III
· 2016
[cited by applicant]
US 20160304549A1
· Coquerel et al.
· 2016
[cited by applicant]
Ahmed, Z., Bacterial L-Ribose and L-arabinose Isomerase: Production, Isolation, Immbolization and Characterization, Bangladesh J. Sci. Ind. Res., 25:89-104 (2000).
[cited by applicant]
Ahmed, Z., Biochemical Preparation of L-Ribose and L-Arabinose from Ribitol: A New Approach, Journal of Bioscience and Bioengineering, 88(4):444-448 (1999).
[cited by applicant]
Banker, G.S. et al., Modern Pharmaceutics, 3ed., Marcel Dekker, New York, 596 (1996).
[cited by applicant]
Beigelman, L., Epimerization During the Acetolysis of 3-O-Acetyl-5-O-Benzoyl-1,2-O-Isopropylidene-3-C-Methyl-?-D-Ribofuranose. Synthesis of 3′-C-Methylnucleosides with the ?-D-ribo- and ?-D-arabino Configurations, Carbo…
[cited by applicant]
Benner, S., Understanding Nucleic Acids Using Synthetic Chemistry, Acc. Chem. Res., 37:784-797 (2004).
[cited by applicant]
Biron, K.K. et al., Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action, Antimicrob. Agents Chemother., 46(8):2365-2372 (2002).
[cited by applicant]
Chulay, J. et al., Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease, Adv. Exp. Med. Biol., 458:129-134 (1999).
[cited by applicant]
Kelley, J., Furanose-Pyranose Isomerization of Reduces Pyrimidine and Cyclic Urea Ribosides, J. Med. Chem., 29:2351-2358 (1986).
[cited by applicant]
Kern, E.R. et al., Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections, Antimicrob Agents Chemother., 48(5):1749-1755 (2004).
[cited by applicant]
Koszalka, G.W. et al., Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication, Antimicrob. Agents Chemother., 46(8):2373-2380 (2002).
[cited by applicant]
Lalezari, J.P. et al., Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV…
[cited by applicant]
Okano, K., Synthesis and pharmaceutical application of L-ribose, Tetrahedron, 65:1937-1949 (2009).
[cited by applicant]
Samuel, J., Mechanistic aspects of enzymatic carbohydrate epimerization, Nat. Prod. Rep., 19:261-277 (2002).
[cited by applicant]
ViroPharma Press Release dated Feb. 9, 2009.
[cited by applicant]
ViroPharma Press Release dated Mar. 29, 2006.
[cited by applicant]
Wang, L.H. et al., Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti- human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects, Antimicrob. Agents Chemother., 47 (…
[cited by applicant]
Williams, S.L. et al., In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses, Antimicrob. Agents Chemother., 47(7):2186-2192 (2003).
[cited by applicant]
Wolff, M.E., Burger's Medicinal Chemistry, 5ed, Part I, John Wiley & Sons, 975-977 (1995).
[cited by applicant]